martes, 6 de octubre de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 24, 2026

Palantir Drops 5% as Tech Sells Off: Is PLTR Being Punished Unfairly?

View original at finance.yahoo.com

Palantir Drops 5% as Tech Sells Off: Is PLTR Being Punished Unfairly? Quick Read Palantir Technologies (PLTR) posted Q4 2025 revenue of $1.406B, up 70% year-over-year, with free cash flow of $791M, while guidance for 2026 revenue is $7.2B (61% growth) with U.S…

Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

Palantir is an n of 1 (unique in the market)
60% confidence
U.S. commercial revenue grew 137% year-over-year
60% confidence
Palantir's Rule of 40 score is now an incredible 127%
60% confidence
U.S. revenue grew 93% year-over-year last quarter
60% confidence
Announcing a 2026 revenue growth guide of 61% year-over-year
60% confidence

Data points we hold from this source

NASDAQ · index change

-1 percent

Lo que sabemos · la inteligencia detrás de esta página

En vivo desde el sustrato

Lo que estamos viendo

Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave

Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.

Nuestra lectura de los datos ›

Señales que seguimos

Satellite-Terrestrial Network Integration Acceleration

Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

Patrones que observamos ›

Donde las fuentes discrepan

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Señalamos los conflictos abiertamente ›

Verificado recientemente

✓ Verificado con la fuente original

4,985

hechos rastreados a su fuente — y señalamos los que no se sostienen.

101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados

Consulta estos datos → isubstrate.com

Palantir Drops 5% as Tech Sells Off: Is PLTR Being Punished Unfairly? — Source | Via News | es.VIA.NEWS